K-ras gene mutation – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Tue, 16 Jun 2026 04:02:18 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png K-ras gene mutation – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of divarasib and pembrolizumab compared to standard chemotherapy in previously untreated KRAS G12C-mutated advanced non-small cell lung cancer https://clinicaltrials.eu/trial/study-of-divarasib-and-pembrolizumab-compared-to-standard-chemotherapy-in-previously-untreated-kras-g12c-mutated-advanced-non-small-cell-lung-cancer/ Thu, 30 Apr 2026 13:08:12 +0000 https://clinicaltrials.eu/trial/study-of-divarasib-and-pembrolizumab-compared-to-standard-chemotherapy-in-previously-untreated-kras-g12c-mutated-advanced-non-small-cell-lung-cancer/ This study focuses on Non-Small Cell Lung Cancer that is advanced or has spread to other parts of the body (metastatic), specifically in patients who have not received previous treatment and whose cancer has a specific genetic change called KRAS G12C mutation. The study will test a combination of medications including divarasib (also known as GDC-6036) and pembrolizumab (KEYTRUDA) compared to a combination of pembrolizumab with pemetrexed and either carboplatin or cisplatin.

The study aims to determine whether the combination of divarasib and pembrolizumab works better than the standard treatment combination in treating this type of lung cancer. The medications will be given through different routes – divarasib as tablets taken by mouth, while pembrolizumab, pemetrexed, carboplatin, and cisplatin are given through an intravenous infusion (through a vein).

During the study, doctors will monitor how the cancer responds to treatment and track any side effects that may occur. They will also assess how the treatment affects patients’ quality of life and symptoms related to their cancer, such as cough and breathing difficulties. The study will measure how long patients live without their cancer getting worse and their overall survival time.

]]> A study of pembrolizumab, cetuximab, and MK-1084 for patients with advanced or metastatic non-small cell lung cancer with KRAS G12C mutations https://clinicaltrials.eu/trial/a-study-of-pembrolizumab-cetuximab-and-mk-1084-for-patients-with-advanced-or-metastatic-non-small-cell-lung-cancer-with-kras-g12c-mutations/ Wed, 29 Apr 2026 15:09:05 +0000 https://clinicaltrials.eu/trial/a-study-of-pembrolizumab-cetuximab-and-mk-1084-for-patients-with-advanced-or-metastatic-non-small-cell-lung-cancer-with-kras-g12c-mutations/ This study is for people with Nonsquamous Non-small Cell Lung Cancer, a type of lung cancer that does not involve certain specific cell shapes, which has spread or is at an advanced stage. The research focuses on patients who specifically have a KRAS G12C mutation, which is a change in the genetic code of the cancer cells. The purpose of the study is to evaluate the safety and effectiveness of different combinations of new treatments.

Participants may receive several different medications. These include cetuximab, which is given through an intravenous infusion, a method of delivering medicine directly into a vein, and MK-1084, which is taken as a pill. Other medications being studied include pembrolizumab, also given by intravenous infusion. Some people may receive a combination of these new drugs, while others may receive standard treatments like carboplatin or pemetrexed.

During the study, different groups of participants will be assigned to receive different combinations of these medicines to see which ones work best. The process involves regular monitoring to see how the body reacts to the treatments and how the cancer changes over time.

]]> Study of MK-1084, cetuximab and mFOLFOX6 combination compared to mFOLFOX6 with or without bevacizumab for patients with KRAS G12C-mutant advanced colorectal cancer https://clinicaltrials.eu/trial/study-of-mk-1084-cetuximab-and-mfolfox6-combination-compared-to-mfolfox6-with-or-without-bevacizumab-for-patients-with-kras-g12c-mutant-advanced-colorectal-cancer/ Wed, 29 Apr 2026 15:06:29 +0000 https://clinicaltrials.eu/trial/study-of-mk-1084-cetuximab-and-mfolfox6-combination-compared-to-mfolfox6-with-or-without-bevacizumab-for-patients-with-kras-g12c-mutant-advanced-colorectal-cancer/ This clinical trial focuses on treating patients with Colorectal Cancer that is locally advanced, cannot be surgically removed, or has spread to other parts of the body (metastatic). Specifically, the cancer must have a particular genetic change called KRAS G12C mutation. The study will test a new drug called MK-1084 in combination with other cancer treatments including cetuximab (a targeted therapy) and mFOLFOX6 (a combination chemotherapy that includes oxaliplatin, fluorouracil, and calcium folinate).

The study will compare two different treatment approaches: one group will receive MK-1084, cetuximab, and mFOLFOX6, while the other group will receive mFOLFOX6 either alone or with another drug called bevacizumab. The main purpose is to determine if adding MK-1084 and cetuximab to standard chemotherapy is safe and effective for treating this specific type of colorectal cancer.

During the study, patients will receive their assigned treatments through a combination of oral tablets (MK-1084) and intravenous infusions (other medications). The medications will be given according to a specific schedule, and patients will be monitored regularly to assess how well the treatment is working and to check for any side effects.

]]> Study Comparing Divarasib, Sotorasib, and Adagrasib for Patients with Advanced or Metastatic KRAS G12C-Positive Non-Small Cell Lung Cancer https://clinicaltrials.eu/trial/study-comparing-divarasib-sotorasib-and-adagrasib-for-patients-with-advanced-or-metastatic-kras-g12c-positive-non-small-cell-lung-cancer/ Wed, 29 Apr 2026 15:00:33 +0000 https://clinicaltrials.eu/trial/study-comparing-divarasib-sotorasib-and-adagrasib-for-patients-with-advanced-or-metastatic-kras-g12c-positive-non-small-cell-lung-cancer/ This clinical trial is focused on studying a type of lung cancer known as KRAS G12C-positive advanced or metastatic non-small cell lung cancer. This is a form of lung cancer that has a specific genetic mutation called KRAS G12C, which can make the cancer more challenging to treat. The study is comparing the effectiveness and safety of a new treatment called divarasib against two existing treatments, sotorasib and adagrasib. These treatments are designed to target the KRAS G12C mutation and are taken as film-coated tablets.

The purpose of the study is to evaluate how well these treatments work in preventing the cancer from getting worse, which is known as progression-free survival. Participants in the study will be randomly assigned to receive either divarasib, sotorasib, adagrasib, or a placebo. The study will monitor the participants over a period of time to see how the treatments affect their cancer and overall health. This includes looking at how long the treatments can keep the cancer from progressing and any side effects that may occur.

Throughout the study, participants will have regular check-ups and tests to assess their health and the status of their cancer. The study aims to provide valuable information on the best treatment options for patients with KRAS G12C-positive advanced or metastatic non-small cell lung cancer, potentially leading to improved outcomes for those affected by this condition.

]]> Study of JDQ443, TNO155, and Tislelizumab for Patients with Advanced Solid Tumors with KRAS G12C Mutation https://clinicaltrials.eu/trial/study-of-jdq443-tno155-and-tislelizumab-for-patients-with-advanced-solid-tumors-with-kras-g12c-mutation/ Wed, 29 Apr 2026 14:59:59 +0000 https://clinicaltrials.eu/trial/study-of-jdq443-tno155-and-tislelizumab-for-patients-with-advanced-solid-tumors-with-kras-g12c-mutation/ This clinical trial is focused on studying advanced solid tumors that have a specific change in the KRAS gene, known as the KRAS G12C mutation. The study is testing a new treatment called JDQ443, which is being evaluated both on its own and in combination with other treatments. These additional treatments include TNO155 and tislelizumab. The purpose of the study is to understand the safety and how well these treatments work together.

Participants in the study will receive the treatments in different forms, such as tablets or capsules for oral use, and a solution for infusion, which is given through a vein. The study will be conducted in two main parts. The first part will focus on finding the best dose of JDQ443 alone and in combination with the other treatments. The second part will look at how effective these treatments are in shrinking the tumors and improving the condition of the patients.

Throughout the study, the safety of the treatments will be closely monitored by checking for any side effects or changes in health. The study aims to find the most suitable dose and treatment plan for future research, with the hope of providing new options for patients with advanced cancers that have the KRAS G12C mutation.

]]> Study on Sotorasib for Patients with Advanced KRAS G12C-Mutated Non-Small Cell Lung Cancer and Comorbidities https://clinicaltrials.eu/trial/study-on-sotorasib-for-patients-with-advanced-kras-g12c-mutated-non-small-cell-lung-cancer-and-comorbidities/ Wed, 29 Apr 2026 14:56:56 +0000 https://clinicaltrials.eu/trial/study-on-sotorasib-for-patients-with-advanced-kras-g12c-mutated-non-small-cell-lung-cancer-and-comorbidities/ This clinical trial is focused on studying a type of lung cancer known as KRAS G12C-mutated non-small cell lung cancer. This is a specific form of lung cancer that has a particular genetic mutation called KRAS G12C. The trial is testing a medication called sotorasib, which is taken as a film-coated tablet. Sotorasib is an enzyme inhibitor, meaning it works by blocking certain proteins that help cancer cells grow.

The purpose of the study is to see how effective sotorasib is in reducing the size of tumors in patients with this type of lung cancer. Participants in the study will receive sotorasib and will be monitored over time to observe changes in their tumor size and overall health. The study will also look at how long patients can live without their disease getting worse and how long they respond to the treatment. Some patients may receive a placebo, which is a substance with no active medication, to compare the effects of sotorasib.

Throughout the study, various health assessments will be conducted to ensure the safety and well-being of the participants. These assessments will include monitoring for any side effects, changes in vital signs, and laboratory tests. The study aims to gather information on how sotorasib affects patients with different health conditions and how it interacts with other treatments they may have received. The trial is expected to continue until 2028, providing valuable insights into the treatment of KRAS G12C-mutated non-small cell lung cancer.

]]> Study of adagrasib in elderly patients (70 years or older) or patients with poor performance status who have KRAS G12C mutation-positive non-small cell lung cancer https://clinicaltrials.eu/trial/study-of-adagrasib-for-patients-with-krasg12c-mutant-non-small-cell-lung-cancer-including-elderly-or-those-with-poor-health/ Wed, 29 Apr 2026 14:47:49 +0000 https://clinicaltrials.eu/trial/study-of-adagrasib-for-patients-with-krasg12c-mutant-non-small-cell-lung-cancer-including-elderly-or-those-with-poor-health-2/ This study focuses on treating patients with non-small cell lung cancer (NSCLC) that has a specific genetic change called KRASG12C mutation. The study will evaluate a medication called adagrasib (also known as MRTX849), which is given as a film-coated tablet that patients take by mouth. This drug works by blocking a specific protein that contributes to cancer growth.

The research aims to determine how well adagrasib works in treating two specific groups of patients: elderly individuals (70 years and older) and those who have more difficulty performing daily activities due to their cancer. The medication is designed to specifically target lung cancer cells that have the KRASG12C mutation, which is a change in the genetic material of cancer cells.

During the study, participants will receive adagrasib tablets daily. The treatment may continue for up to 13 months, with regular check-ups to monitor how well the treatment is working and any side effects. The maximum daily dose of the medication is 1200 milligrams. Doctors will evaluate how the tumors respond to treatment, how long the treatment remains effective, and how it affects patients’ overall health and well-being.

]]> Study of Sotorasib Treatment in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) with KRAS G12C Mutation Who Have Previously Received Treatment https://clinicaltrials.eu/trial/study-of-sotorasib-for-patients-with-previously-treated-advanced-or-metastatic-non-small-cell-lung-cancer-with-kras-g12c-mutation/ Wed, 29 Apr 2026 14:29:55 +0000 https://clinicaltrials.eu/trial/study-of-sotorasib-for-patients-with-previously-treated-advanced-or-metastatic-non-small-cell-lung-cancer-with-kras-g12c-mutation/ This study focuses on non-small cell lung cancer (NSCLC) that has spread to other parts of the body (metastatic) or is locally advanced and cannot be surgically removed. Specifically, it looks at cases where the cancer has a particular genetic change called KRAS G12C mutation. The study will use a medication called sotorasib (also known as LUMYKRAS or AMG 510), which is given as tablets taken by mouth.

The purpose of this research is to understand how tumors respond to treatment after 4 months and to identify biological markers that might explain why some patients stop responding to the treatment. The study will involve patients who have already received at least one previous treatment for their advanced lung cancer.

During the study, participants will take sotorasib tablets daily. They will have regular medical check-ups and imaging scans every 8 weeks to monitor how their cancer responds to treatment. The study also includes collecting tissue samples before, during, and after treatment to better understand how the medication works and why some cancers might become resistant to it.

]]> Study of JDQ443 and Ribociclib in Combination for Adult Patients with Advanced Solid Tumors with KRAS G12C Mutation https://clinicaltrials.eu/trial/study-of-jdq443-and-ribociclib-in-combination-for-adult-patients-with-advanced-solid-tumors-with-kras-g12c-mutation/ Wed, 29 Apr 2026 14:25:39 +0000 https://clinicaltrials.eu/trial/study-of-jdq443-and-ribociclib-in-combination-for-adult-patients-with-advanced-solid-tumors-with-kras-g12c-mutation/ This clinical trial is focused on studying treatments for patients with advanced cancer that has a specific mutation called KRAS G12C. The study involves patients with different types of solid tumors, including those that are metastatic, meaning the cancer has spread to other parts of the body, or unresectable, meaning it cannot be removed with surgery. The main purpose of the study is to explore the safety and effectiveness of various treatment combinations.

The treatments being tested include a medication with the code name JDQ443, which is taken as a tablet. Other medications involved in the study are LEE011 (known as ribociclib), Mekinist (known as trametinib), and TMT212 (a form of trametinib dimethyl sulfoxide). Additionally, Cetuximab, which is given as an infusion into a vein, is also part of the study. Some patients may receive a placebo, which is a substance with no active medication, to compare the effects of the actual treatments.

The study is conducted in two phases. The first phase involves gradually increasing the dose of the medications to determine the safest and most effective dose. The second phase assesses how well the treatments work in controlling the cancer. Participants will take the medications as directed and attend regular check-ups to monitor their health and the cancer’s response to the treatment. The study aims to find the best treatment combinations for future use in patients with this specific genetic mutation.

]]> Study of BMS-986466 with Adagrasib and Cetuximab for Patients with KRAS G12C-mutant Advanced Solid Tumors https://clinicaltrials.eu/trial/study-of-bms-986466-with-adagrasib-and-cetuximab-for-patients-with-kras-g12c-mutant-advanced-solid-tumors/ Wed, 29 Apr 2026 14:25:19 +0000 https://clinicaltrials.eu/trial/study-of-bms-986466-with-adagrasib-and-cetuximab-for-patients-with-kras-g12c-mutant-advanced-solid-tumors/ This clinical trial is focused on studying advanced solid tumors that have a specific mutation known as KRAS G12C. The types of cancer being studied include non-small cell lung cancer (NSCLC), colorectal cancer (CRC), pancreatic duct adenocarcinoma (PDAC), and biliary tract cancer (BTC). The trial will test a new treatment combination involving a medication called BMS-986466 with another drug named adagrasib, and in some cases, a third drug called cetuximab. The purpose of the study is to determine if this combination is safe and effective for patients with these types of cancer.

The study is divided into two parts. In the first part, patients with advanced KRAS G12C mutant cancers will receive BMS-986466 with adagrasib, and some will also receive cetuximab. The goal is to find the safest dose that patients can tolerate. In the second part, the study will compare the effectiveness of the treatment combinations. For patients with NSCLC, the study will compare BMS-986466 with adagrasib against adagrasib alone. For those with CRC, the study will compare BMS-986466 with adagrasib and possibly cetuximab against adagrasib plus cetuximab.

Throughout the study, researchers will monitor for any side effects and measure how well the treatment works against the cancer. The study aims to identify the best dose levels for further testing and to see if the treatment can help control the cancer. The trial is expected to continue until 2028, with recruitment starting in 2024.

]]>